R Tal-Singer Lung Health Researcher & Advocate 🫁

A Scientific leader, innovator & expert in the Respiratory field. Driver of pre-competitive patient-focused international partnerships and collaborations.

[Global Allergy & Airways Patient Platform @gaapporg]

Tomorrow, on World #EoEDay, we're hosting a multidisciplinary webinar dedicated to advancing the global understanding of EoE. 🕓 13:00 Central Europe Time
📍 REGISTER: https://t.co/rYa6lhw3TL
.
#FoodShouldNotHurt

[R Tal-Singer Lung Health Researcher & Advocate 🫁 @rtalsinger1]

Last day at the excellent conference #ATS2026 … exciting time in Respiratory with a bright future of new #diagnostics, novel #endpoints, a growing interest in early interventions and lots of data shared by @gaapporg !
@COPDKristen

[Global Allergy & Airways Patient Platform @gaapporg]

Meet the new #AsthmaCareMap: A tool for concrete examples and evidence of asthma-based research. It compiles 1,937 research insights from 153 peer-reviewed publications, public health reports, and clinical guidelines into a single, organized resource.
🔗 https://t.co/74YcpSH0T3

[R Tal-Singer Lung Health Researcher & Advocate 🫁 @rtalsinger1]

#GOLD0 in #COPDGene are being treated with respiratory medications yet evidence generation studies still exclude them #ATS2026

[R Tal-Singer Lung Health Researcher & Advocate 🫁 @rtalsinger1]

IIa there a potential for combining #CAAT and 5STS as simple tools for for evaluation of exercise tolerance in primary care? @AlanLHamilton
https://t.co/kYKNq8j6Pu

[Global Allergy & Airways Patient Platform @gaapporg]

#ICAN2026: Call for abstracts for early career researchers (5 September, Barcelona). Topics: Immune mechanisms and treatment response to AI, imaging, and novel therapies. Selected abstracts receive travel, accommodation support. Deadline extended: 22 May 🔗https://t.co/L7kS5fJ2eH

[Global Allergy & Airways Patient Platform @gaapporg]

#ICAN2026: Call for abstracts for early career researchers (5 September, Barcelona). Topics: Immune mechanisms and treatment response to AI, imaging, and novel therapies. Selected abstracts receive travel support + accommodation. Deadline: 15 April, 2026 🔗https://t.co/L7kS5fJ2eH

[Global Allergy & Airways Patient Platform @gaapporg]

Learn more: https://t.co/fHJo61WwV2
#TheMissingPiece #UnitedForAlpha1 #SupportedbyGAAPP

[James D Chalmers @ProfJDChalmers]

Both 10mg and 25mg brensocatib has been approved in the US for treatment of bronchiectasis.
In the absence of official guidance, Chuck Daley and i comment on optimal dosing, concluding that 25mg should be the preferred dose for patients
@ATSBlueEditor
https://t.co/qrSUlAh7R9

[Global Allergy & Airways Patient Platform @gaapporg]

Call for Abstracts for Early Career Researchers: share your work at ICAN 2026 (5 September, Barcelona). Join a collaborative community advancing respiratory research — from immune mechanisms and treatment response to AI, imaging, and novel therapies. Connect with peers and global experts across academia, industry, NIH, ERS, and more. Only 50 abstracts will be selected.
✈️ Selected abstracts will receive travel support + accommodation
📅 Deadline: 15 April, 2026
🔗 https://t.co/3Rg9qNxw30

[R Tal-Singer Lung Health Researcher & Advocate 🫁 @rtalsinger1]

Congratulations to @gaapporg #CERT Governance Board members, patient advocates and GSK collaborators on our publication describing the translation, linguistic, and cross-cultural validation of the #COPD Exacerbation Recognition Tool.
https://t.co/4GJLG1ndTU

[James D Chalmers @ProfJDChalmers]

Check our new interactive learning module on bronchiectasis - talking about the new ERS guidelines and much more with Sanjay Chotirmall and Natalie Lorent ❤️

[James D Chalmers @ProfJDChalmers]

What about the other pathogens i hear you say?
@alferes_de and @lifearc1 have you covered
Rapid rRNA detection of H. influenzae, S. aureus, S. pneumoniae and M. catarrhalis in bronchiectasis sputum. Better than culture- the future of micro is molecular!
https://t.co/jGgsdrFoWd

[James D Chalmers @ProfJDChalmers]

Our latest paper just out in @LancetRespirMed
10 unanswered questions about DPP1 inhibition in bronchiectasis

We outline key future clinical and research questions after the approval of the first new therapy for people with bronchiectasis.
Congratulations Jiahui, Chloe and @MereteLong

[Global Allergy & Airways Patient Platform @gaapporg]

In celebration of International Women’s Day, join us for the next #GAAPPAcademy webinar! 9 global experts share their journey with leadership and community impact as they discuss “The Role of Women in Patient Advocacy”.

🗓 9 March 2026 🕒 15:00 CET 🔗 Register: https://t.co/wYwCnKJpur

[R Tal-Singer Lung Health Researcher & Advocate 🫁 @rtalsinger1]

📣 A big step for patient-centred, evidence-based respiratory care.

The #CAAT & #CERT tools — coordinated by Governance Boards at @gaapporg — are now included in the 2026 German National #COPD Guidelines 🇩🇪

🔗 https://t.co/ngWJfkk6KU
#RespiratoryHealth #PatientCare

[R Tal-Singer Lung Health Researcher & Advocate 🫁 @rtalsinger1]

New publication 📢
US survey (n=3,024) of adults with chronic conditions shows favorable attitudes toward flu/COVID vaccines & antivirals.
Risk perception strongly linked to uptake. https://t.co/WELGtCDE4d
#Vaccines #PublicHealth #COPD #Asthma #diabetes
@gaapporg @COPDKristen

[R Tal-Singer Lung Health Researcher & Advocate 🫁 @rtalsinger1]

Take the quiz to find out how well you understand #bronchiectasis

[Global Allergy & Airways Patient Platform @gaapporg]

Let’s talk about bronchiectasis!

This chronic lung disease affects people of all ages across the globe—but it’s often
misunderstood.

Can it be treated? Is it contagious? Take our short quiz to learn the facts and feel more
informed.

Take the quiz here ➡️ https://t.co/TgfKEg7MWe

[James D Chalmers @ProfJDChalmers]

Brensocatib did not meet primary or secondary endpoints in the phase 2 BIRCH study in chronic rhinosinusitis without nasal polyps.
Difficult/complex disease and interested to see the full data. Safety reassuring as with previous studies in bronchiectasis
https://t.co/sXhUjjBJVV

[Global Allergy & Airways Patient Platform @gaapporg]

Chronic Spontaneous Urticaria Study: Enrolling now.

✅ Reimbursement for travel
✅ No-cost study-related care from local doctors

Click here to see if you qualify and if there is a study site near you in
United States: https://t.co/cI9l9F062Z
Argentina: https://t.co/usBXVQLGq5
Canada: https://t.co/npDBsA02BP
Chile: https://t.co/WqTVdm74zH
Colombia: https://t.co/6UFIwMdSGK

#EMBARQ-CSU